Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma-Reference-Cited by-同舟云学术

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Published:2016-12-30 Issue:12 Volume:23 Page:3012-3024
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Dong Zhong-Yi,Zhong Wen-Zhao,Zhang Xu-Chao,Su Jian,Xie Zhi,Liu Si-Yang,Tu Hai-Yan,Chen Hua-Jun,Sun Yue-Li,Zhou Qing,Yang Jin-Ji,Yang Xue-Ning,Lin Jia-Xin,Yan Hong-Hong,Zhai Hao-Ran,Yan Li-Xu,Liao Ri-Qiang,Wu Si-Pei,Wu Yi-Long

Funder

Guangzhou Science and Technology Bureau

The National Key Research and Development Program of China

National Natural Science Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 738 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDM2 inhibitors in cancer immunotherapy: Current status and perspective;Genes & Diseases;2024-11

2. The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma;Pathology;2024-10

3. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

4. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy;Journal of Cancer Research and Clinical Oncology;2024-09-07

5. Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy;Lung Cancer;2024-09